Neurocrine Biosciences (NBIX) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 18.04% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 39.10% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 18.31% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 43.42% |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | -8.76% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.76% |
| Mar 31, 2026 | 46.81% |
| Dec 31, 2025 | 39.52% |
| Sep 30, 2025 | 32.05% |
| Jun 30, 2025 | -9.61% |
| Mar 31, 2025 | 53.26% |
| Dec 31, 2024 | 286.50% |
| Sep 30, 2024 | 36.74% |
| Jun 30, 2024 | -14.46% |
| Mar 31, 2024 | 14.28% |
| Dec 31, 2023 | 9.33% |
| Sep 30, 2023 | 131.41% |
| Jun 30, 2023 | 14.74% |
| Mar 31, 2023 | -76.80% |
| Dec 31, 2022 | 13.62% |
| Sep 30, 2022 | 0.34% |
| Jun 30, 2022 | 29.09% |
| Mar 31, 2022 | 28.86% |
| Dec 31, 2021 | -56.35% |
| Sep 30, 2021 | -3.57% |